

Title (en)  
SPECIFIC HUMAN ANTIBODIES

Title (de)  
SPEZIFISCHE HUMANE ANTIKÖRPER

Title (fr)  
ANTICORPS HUMAINS SPECIFIQUES

Publication  
**EP 1646401 A4 20070718 (EN)**

Application  
**EP 04777349 A 20040630**

Priority  
• US 2004021099 W 20040630  
• US 61084003 A 20030630

Abstract (en)  
[origin: WO2005005455A2] The present invention provides antibodies that bind an epitope of PSGL-1 comprising the motif D-X-Y-D, wherein X represents any amino acid or the covalent linkage between D and Y, and Y is sulfated, which antibody can be complexed with one or more copies of an agent. The antibodies of the invention can be used in a method of inducing antibody-dependent cell cytotoxicity and/or stimulating natural killer (NK) cells or T cells. In addition, by administering these antibodies to a patient in need thereof, a method of inducing cell death is provided. A method of preventing infection by a virus (e.g., HIV) by administering to a patient in need thereof an antibody of the present invention is also provided. The present invention also provides a method of introducing an agent into a cell that expresses sulfated PSGL-1 by coupling or complexing an agent to an antibody of the present invention and administering the complex to the cell. Finally, the present invention provides methods of diagnosis, prognosis and staging using the present antibodies.

IPC 8 full level  
**A61K 39/395** (2006.01); **A61K 47/48** (2006.01); **A61P 35/00** (2006.01); **C07K 16/06** (2006.01); **C07K 16/28** (2006.01); **C07K 16/36** (2006.01); **C07K 16/44** (2006.01); **C12N 5/07** (2010.01); **C12N 5/0783** (2010.01); **C12N 5/09** (2010.01); **G01N 33/574** (2006.01); **A61P 31/18** (2006.01)

CPC (source: EP KR)  
**A61K 31/65** (2013.01 - KR); **A61K 47/6809** (2017.07 - EP); **A61K 47/6849** (2017.07 - EP); **A61P 7/02** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 16/06** (2013.01 - KR); **C07K 16/28** (2013.01 - KR); **C07K 16/2896** (2013.01 - EP); **C07K 16/36** (2013.01 - EP); **C07K 16/44** (2013.01 - EP); **C07K 2317/34** (2013.01 - EP); **C07K 2317/52** (2013.01 - EP); **C07K 2317/622** (2013.01 - EP); **C07K 2317/732** (2013.01 - EP); **C07K 2317/734** (2013.01 - EP); **C07K 2317/77** (2013.01 - EP); **C07K 2319/00** (2013.01 - EP)

Citation (search report)  
• [X] WO 02059264 A2 20020801 - BIO TECHNOLOGY GENERAL CORP [US], et al  
• [X] WO 02053700 A2 20020711 - BIO TECHNOLOGY GENERAL CORP [US]  
• [X] US 2002068813 A1 20020606 - DRAGIC TATJANA [US], et al  
• [X] SNAPP ET AL: "A novel P- selectin glycoprotein ligand-1 monoclonal antibody recognizes an epitope within the tyrosine sulfate motif of human PSGL-1 and blocks recognition of both P- and L- selectin", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 91, no. 1, 1998, pages 154 - 164, XP002123922, ISSN: 0006-4971  
• [A] THATTE ARAVINDA ET AL: "Binding of function-blocking mAbs to mouse and human P-selectin glycoprotein ligand-1 peptides with and without tyrosine sulfation.", JOURNAL OF LEUKOCYTE BIOLOGY SEP 2002, vol. 72, no. 3, September 2002 (2002-09-01), pages 470 - 477, XP002432443, ISSN: 0741-5400  
• [X] KAPPELMAYER J ET AL: "Identification of P-selectin glycoprotein ligand-1 as a useful marker in acute myeloid leukaemias.", BRITISH JOURNAL OF HAEMATOLOGY DEC 2001, vol. 115, no. 4, December 2001 (2001-12-01), pages 903 - 909, XP002432444, ISSN: 0007-1048  
• [X] AWWAD M ET AL: "MODIFICATION OF MONOCLONAL ANTIBODY CARBOHYDRATES BY OXIDATION, CONJUGATION, OR DEOXYMANNOJIRIMYCIN DOES NOT INTERFERE WITH ANTIBODY EFFECTOR FUNCTIONS", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 38, 1994, pages 23 - 30, XP008062172, ISSN: 0340-7004  
• [DX] TRAIL PAMELA A ET AL: "Monoclonal antibody drug immunoconjugates for targeted treatment of cancer", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 52, no. 5, May 2003 (2003-05-01), pages 328 - 337, XP002392220, ISSN: 0340-7004  
• [X] STEEGMAIER M ET AL: "P-selectin glycoprotein ligand-1 mediates rolling of mouse bone marrow-derived mast cells on P-selectin but not efficiently on E-selectin.", EUROPEAN JOURNAL OF IMMUNOLOGY JUN 1997, vol. 27, no. 6, June 1997 (1997-06-01), pages 1339 - 1345, XP002432445, ISSN: 0014-2980  
• [X] BORGES E ET AL: "THE P-SELECTIN GLYCOPROTEIN LIGAND-1 IS IMPORTANT FOR RECRUITMENT OF NEUTROPHILS INTO INFLAMED MOUSE PERITONEUM", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 90, no. 5, 1 September 1997 (1997-09-01), pages 1934 - 1942, XP000952862, ISSN: 0006-4971  
• [X] YANG J ET AL: "The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction.", THROMBOSIS AND HAEMOSTASIS JAN 1999, vol. 81, no. 1, January 1999 (1999-01-01), pages 1 - 7, XP002432446, ISSN: 0340-6245  
• [PX] ZANARDO RENATA C O ET AL: "A down-regulatable E-selectin ligand is functionally important for PSGL-1-independent leukocyte-endothelial cell interactions.", BLOOD 1 DEC 2004, vol. 104, no. 12, 1 December 2004 (2004-12-01), pages 3766 - 3773, XP002432447, ISSN: 0006-4971  
• [X] NORMAN K E ET AL: "Leukocyte rolling in vivo is mediated by P-selectin glycoprotein ligand-1.", BLOOD 15 DEC 1995, vol. 86, no. 12, 15 December 1995 (1995-12-15), pages 4417 - 4421, XP002432448, ISSN: 0006-4971  
• [A] THATTE ARAVINDA ET AL: "Sulfation-independent recognition of PSGL-1 peptides by mAbs KPL-1 and PL-1", FASEB JOURNAL, vol. 15, no. 5, 8 March 2001 (2001-03-08), & ANNUAL MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY ON EXPERIMENTAL BIOL; ORLANDO, FLORIDA, USA; MARCH 31-APRIL 04, 2001, pages A866, XP008078463, ISSN: 0892-6638  
• See references of WO 2005005455A2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**WO 2005005455 A2 20050120; WO 2005005455 A3 20060216;** AU 2004256113 A1 20050120; BR PI0411944 A 20070102; CA 2531283 A1 20050120; CN 1897970 A 20070117; EP 1646401 A2 20060419; EP 1646401 A4 20070718; IL 172511 A0 20060410; JP 2007527393 A 20070927; KR 20060107501 A 20061013; MX PA06000253 A 20070308; RU 2006102571 A 20070820

DOCDB simple family (application)

**US 2004021099 W 20040630**; AU 2004256113 A 20040630; BR PI0411944 A 20040630; CA 2531283 A 20040630;  
CN 200480024911 A 20040630; EP 04777349 A 20040630; IL 17251105 A 20051212; JP 2006518747 A 20040630;  
KR 20067000219 A 20051230; MX PA06000253 A 20040630; RU 2006102571 A 20040630